Για οποιαδήποτε επιπλέον πληροφορία ή διευκρίνιση χρειαστείτε, παρακαλούμε επικοινωνήστε μαζί μας.
Βάλια Τασιοπούλου
Brand Manager, Neuroscience & Rare Diseases
IPSEN Greece, Cyprus & Israel
Tel.:
+30 693 494 7440
Email:
vaia.tasiopoulou@ipsen.com
Βιβλιογραφία:
National Organization for Rare Disorders. Rare Disease Database: Alagille Syndrome. Available at: https:// rarediseases.org/rarediseases/alagille syndrome. Accessed April 2024.
National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts for Alagille Syndrome. Available at: https://www.niddk.nih.gov/health-information/liver-disease/alagille-syndrome/definition-facts. Accessed April 2024.
Leonard, LD, et al. 2014. Clinical utility gene card for: Alagille syndrome (ALGS). Eur J Hum Genet. 22(3):435-435.
American Liver Foundation. Alagille Syndrome. Available at: https://liverfoundation.org/liver-diseases/pediatricliver- disease/alagille-syndrome. Accessed April 2024.
Vandriel, SM, et al. (2022). Natural history of liver disease in a large international cohort of children with Alagille Syndrome: Results from the gala study. Hepatol. 77(2):512-529.
Ben AS, et al. 2016. Management of cholestatic pruritus in children with Alagille syndrome: Case report and literature review. Archives de Pédiatrie, 23(12):1247-1250.
Kamath, BM, et al. 2018. Systematic review: The Epidemiology, Natural History, and Burden of Alagille Syndrome. J Pediatr Gastroenterol Nutr. 67(2):148-156.
Kamath, BM, et al. 2020. Outcomes of childhood cholestasis in Alagille syndrome: Results of a Multicenter Observational Study. Hepatol Commun. 4(3):387-398.
Sanchez P, et al. 2021. Therapeutics Development for Alagille Syndrome. Front Pharmacol. 12(704586):2-10.
Αγ. Δημητρίου 63
174 56 ΑΛΙΜΟΣ
Τηλέφωνο:
210 98 58 930
E-mail:
ipsenepe@ipsen.com
http://www.ipsen.gr
ALLSC-GR-000084